Want to see SLDB full AI Analyst Report?
Solid Biosciences (SLDB) Stock Statistics & Valuation Metrics
Total Valuation
Solid Biosciences has a market cap or net worth of $735.51M. The enterprise value is $762.02M.
- Market Cap
- $735.51M
- Enterprise Value
- $762.02M
Share Statistics
Solid Biosciences has 111,610,535 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 111,610,535
- Owned by Insiders
- 11.62%
- Owned by Institutions
- 28.04%
Financial Efficiency
Solid Biosciences’s return on equity (ROE) is -0.97 and return on invested capital (ROIC) is -89.08%.
- Return on Equity (ROE)
- -0.97
- Return on Assets (ROA)
- -0.75
- Return on Invested Capital (ROIC)
- -89.08%
- Return on Capital Employed (ROCE)
- -0.90
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.44M
- Employee Count
- 121
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Solid Biosciences is -3.68. Solid Biosciences’s PEG ratio is -0.14.
- PE Ratio
- -3.68
- PS Ratio
- 0.00
- PB Ratio
- 2.91
- Price to FCF
- -3.53
- Price to Operating Cash Flow
- -5.00
- PEG Ratio
- -0.14
Income Statement
In the last 12 months, Solid Biosciences had revenue of 0 and earned -174.32M in profits. Earnings per share was -1.99.
- Revenue
- 0
- Gross Profit
- -1.64M
- Operating Income
- -179.21M
- Pretax Income
- -174.32M
- Net Income
- -174.32M
- EBITDA
- -172.69M
- Earnings Per Share (EPS)
- -1.99
Cash Flow
In the last 12 months, operating cash flow was -198.92M and capital expenditures -1.38M, giving a free cash flow of -200.30M billion.
- Operating Cash Flow
- -198.92M
- Free Cash Flow
- -200.30M
- Free Cash Flow per Share
- -1.33
Dividends & Yields
Solid Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -28.35%
- Earnings Yield
- -21.63%
Stock Price Statistics
- Beta
- 1.75
- 52-Week Price Change
- 56.35%
- 50-Day Moving Average
- 7.55
- 200-Day Moving Average
- 7.71
- Relative Strength Index (RSI)
- 50.18
- Average Volume (3m)
- 1.20M
Important Dates
Solid Biosciences upcoming earnings date is Mar 16, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 04, 2026
- Next Earnings Date
- Mar 16, 2027
- Ex-Dividend Date
- ―
Financial Position
Solid Biosciences as a current ratio of 6.14, with Debt / Equity ratio of 11.76%
- Current Ratio
- 6.14
- Quick Ratio
- 6.14
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.22
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Solid Biosciences has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Solid Biosciences EV to EBITDA ratio is -2.76, with an EV/FCF ratio of -3.00.
- EV to Sales
- 0.00
- EV to EBITDA
- -2.76
- EV to Free Cash Flow
- -3.00
- EV to Operating Cash Flow
- -3.02
Balance Sheet
Solid Biosciences has $348.93M in cash and marketable securities with $19.62M in debt, giving a net cash position of $329.30M billion.
- Cash & Marketable Securities
- $348.93M
- Total Debt
- $19.62M
- Net Cash
- $329.30M
- Net Cash Per Share
- $2.95
- Tangible Book Value Per Share
- $2.27
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Solid Biosciences is $19.56, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $19.56
- Price Target Upside
- 196.75% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 10
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 28.59%
Scores
- Smart Score
- 10
- AI Score
- 44
